Dermatology 101

Dermatology 101 offers essential information on skin health, common conditions, treatments, and skincare routines, helping individuals understand and care for their skin effectively.


  • Hope for Dystrophic Epidermolysis Bullosa

    Hope for Dystrophic Epidermolysis Bullosa

    Imagine your skin being as delicate as a piece of tissue paper—just a tiny brush against it can cause a blister that won’t heal properly. That’s the everyday reality for people living with dystrophic epidermolysis bullosa (DEB), a rare but deeply impactful genetic skin condition. In this article I’ll walk you through what DEB is, […]

  • Chronic Wounds Explained: Causes, Risks & Healing

    Chronic Wounds Explained: Causes, Risks & Healing

    Ever notice a cut that just won’t quit, no matter how many band‑aids you slap on it? That stubborn sore is what doctors call a chronic wound. In plain language, it’s a skin injury that hangs around longer than four weeks, refusing to follow the normal healing timetable. Why does this happen, and more importantly, […]

  • Otezla results timeline: What to expect & when

    Otezla results timeline: What to expect & when

    Let’s cut to the chase: most folks start seeing a difference in their skin or joints within the first month of taking Otezla, and the biggest improvements usually show up around the 4‑ to 6‑month mark. By the time you hit the one‑year milestone, many are still riding the wave of benefit, with continued gains possible […]

  • Generalized Pustular Psoriasis: Essential Facts & Care

    Generalized Pustular Psoriasis: Essential Facts & Care

    Generalized pustular psoriasis is a rare, severe form of psoriasis that can erupt with painful pustules, fever, and systemic inflammation. Below you’ll find clear, friendly answers on what it is, why flares happen, how doctors diagnose it, and what treatments can keep you safe and comfortable. What Is GPP? Quick definition In plain language, generalized […]

  • Everything You Need to Know About Gomekli Medication

    Everything You Need to Know About Gomekli Medication

    Quick Answer Overview Alright, let’s cut to the chase. Gomekli (generic name mirdametinib) is an oral, small‑molecule MEK inhibitor that the FDA approved in February 2025 for adults and children ≥ 2 years old who live with neurofibromatosis type 1‑plexiform neurofibromas (NF1‑PN). In plain English, it’s a pill that helps slow down the growth of those stubborn tumors that can’t […]

  • Will Medicare Cover Skyrizi? Your Full Guide to Costs and Eligibility

    Will Medicare Cover Skyrizi? Your Full Guide to Costs and Eligibility

    Hey there! If you’ve landed on this page, you’re probably wondering whether Medicare will foot the bill for Skyrizi (risankizumab‑rzaa). The short answer is: yes, it can – but only under the right circumstances. Below, I’ll break everything down in plain‑English, share a few real‑life stories, and give you actionable steps so you can feel […]

  • Gomekli Cost Explained: What You Need to Know Today

    Gomekli Cost Explained: What You Need to Know Today

    Alright, let’s cut to the chase. If you’re wondering how much Gomekli really costs, the short answer is: the wholesale acquisition price sits at $206.25 per milligram, which translates to roughly $18,500 for a typical 42‑capsule, 2 mg supply. But, and there’s always a “but,” the amount you actually pay out‑of‑pocket can be dramatically lower – […]

  • Gomekli Approval: What It Means for You Surely

    Gomekli Approval: What It Means for You Surely

    Did you hear the news? On February 11, 2025 the FDA gave the green light to Gomekli (mirdametinib) for people living with neurofibromatosis‑type 1 (NF1) who have those hard‑to‑treat plexiform neurofibromas. If you or a loved one has been waiting for a real‑world solution, this moment feels like the first sunrise after a long night. In […]

  • Gomekli FDA Approval: What It Means for You and Your Family

    Gomekli FDA Approval: What It Means for You and Your Family

    Big news hit the medical world on February 11 2025: the U.S. Food and Drug Administration gave the green light to Gomekli (generic name mirdametinib). If you or someone you love lives with neurofibromatosis type 1 (NF1) and wrestles with those stubborn plexiform neurofibromas, this approval could feel like a long‑awaited lifeline. Let’s unpack what this means, step by […]

  • Rupioid Psoriasis: Symptoms, Causes & Treatment

    Rupioid Psoriasis: Symptoms, Causes & Treatment

    Rupioid psoriasis is a rare, hyper‑keratotic cousin of the more familiar plaque psoriasis. It creates thick, cone‑shaped plaques that look a lot like little oyster shells stuck to your skin. If you ignore those crusty lesions, they can become painful, bleed, and even invite infection. In the next few minutes we’ll walk through exactly what […]